Search Results - "COCQUYT, V"

Third consensus on medical treatment of metastatic breast cancer by Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C. C., Zwierzina, H.

“…Background: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care…”
Get full text

Imaging requirements for personalized medicine: the oncologists point of view by Kruse, V, Belle, S Van, Cocquyt, V

“…While conventional chemotherapy regimens aim to be cytotoxic against proliferating cells, molecular targeted therapies are directed at specific…”
Get more information

An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial by Neyt, M., Albrecht, J., Cocquyt, V.

“…Background: Herceptin® (trastuzumab) is a humanized monoclonal antibody that is being tested in the adjuvant setting. Cost implications of using trastuzumab,…”
Get full text

Reproducibility of FDG PET based metabolic tumor volume measurements and of their FDG distribution within by Kruse, V, Mees, G, Maes, A, D'Asseler, Y, Borms, M, Cocquyt, V, Van De Wiele, C

“…The aim of this study was to report on the reproducibility of F-18-fluorodeoxyglucose (FDG) PET MTV (metabolic tumor volume) 40% and MTV2.5, as well as on the…”
Get full text

216 Risk for metastases and implications for systemic treatment by Cocquyt, V

Get full text

Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: A corollary study to EORTC trial 18952 by Bouwhuis, M.G, Suciu, S, Kruit, W, Salès, F, Stoitchkov, K, Patel, P, Cocquyt, V, Thomas, J, Liénard, D, Eggermont, A.M.M, Ghanem, G

“…Abstract S100B is a prognostic factor for melanoma as elevated levels correlate with disease progression and poor outcome. We determined its prognostic value…”
Get full text

Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer by De Jaeghere, E., Vandecasteele, K., Claes, K., Makar, A., Tummers, P., Cocquyt, V., Denys, Hannelore

“…DNA repair mechanisms play a key role in oncogenesis and cancer progression in women with BRCA mutation-positive (BRCAm) ovarian cancer (OC). The BRCA1/2 and…”
Get full text

Second consensus on medical treatment of metastatic breast cancer by Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W.J., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C.C., Zwierzina, H.

“…The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on…”
Get full text

A JAK3/STAT3 passenger activation in a lapatinib-acquired resistance model of HER2-amplified breast cancer by Van Bockstal, M, Van Roy, N, Vergauwen, G, Lambein, K, Cocquyt, V, Libbrecht, L, Denys, H, Bracke, M, De Wever, O

Get full text

PARP INHIBITORS IN ONCOLOGY: A NEW SYNTHETIC LETHAL APPROACH TO CANCER THERAPY by Kruse, V, Rottey, S, De Backer, O, Van Belle, S, Cocquyt, V, Denys, H

“…Damage to DNA has emerged as a major culprit in cancer. Mammalian cells are continuously exposed to DNA damage, caused by exogenous toxins as well as…”
Get full text

CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve by Kruse, V, Van de Wiele, C, Borms, M, Maes, A, Pottel, H, Sathekge, M, Cocquyt, V

“…In breast cancer CA 15.3 is considered the tumour marker of choice. CA 15.3 is directly related to the disease extent and to hormone status (estrogen receptor…”
Get more information

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis by Cocquyt, V, Van Belle, S, Reinhardt, R.R, Decramer, M.L.A, O'Brien, M, Schellens, J.H.M, Borms, M, Verbeke, L, Van Aelst, F, De Smet, M, Carides, A.D, Eldridge, K, Gertz, B.J

“…Substance P is localised in brainstem regions associated with emesis. Based on studies in the ferret, it was postulated that a neurokinin-1 (NK1) receptor…”
Get full text

Mutation analysis of P73 and TP53 in Merkel cell carcinoma by VAN GELE, M, KAGHAD, M, DE WOLF-PEETERS, C, DE PAEPE, A, CAPUT, D, SPELEMAN, F, LEONARD, J. H, VAN ROY, N, NAEYAERT, J. M, GEERTS, M. L, VAN BELLE, S, COCQUYT, V, BRIDGE, J, SCIOT, R

“…The p73 gene has been mapped to 1p36.33, a region which is frequently deleted in a wide variety of neoplasms including tumours of neuroectodermal origin. The…”
Get full text

TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES by Van Vlaenderen, I., Canon, J.L., Cocquyt, V., Jerusalem, G., Machiels, J.P., Neven, P., Nechelput, M., Delabaye, I., Gyldmark, M., Annemans, L.

“…Trastuzumab (Herceptin ® , Roche) is a recombinant, humanized monoclonal antibody directed against the neu-HER2 protein, since May 2002 reimbursed in Belgium…”
Get full text

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel by DI LEO, A, CHAN, S, KOREC, S, CROWN, J, SIMMONDS, P, VON MINCKWITZ, G, LEROY, J. Y, DURBECQ, V, ISOLA, J, AAPRO, M, PICCART, M. J, LARSIMONT, D, PAESMANS, M, FRIEDRICHS, K, PINTER, T, COCQUYT, V, MURRAY, E, BODROGI, I, WALPOLE, E, LESPERANCE, B

“…To evaluate the predictive value of HER-2 in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin (A) or with…”
Get full text

A 41-year-old man with breast cancer and dyspnoea: an exceptional complication in an uncommon disease by Buyse, V, Brusselle, G, Cocquyt, V, Van Belle, S

“…A case of advanced breast cancer in a young male, who developed progressive dyspnoea a few months after treatment with chemotherapy is described. The clinical…”
Get full text

Long-term medical costs of postmenopausal breast cancer therapy by Cocquyt, V., Moeremans, K., Annemans, L., Clarys, P., Van Belle, S.

“…Background: Since the incidence of breast cancer is growing, prevention programs can be expected to have a large economic impact on the health care system…”
Get full text

Preceding Sentinel Node Biopsy in Early Breast Cancer: Does it Affect the Number of Axillary Lymph Nodes ? by Braems, G., Denys, H., Cocquyt, V., Van den Broecke, R.

“…In the staging of early breast cancer a positive sentinel node biopsy is followed by axillary dissection in order to assess the number of metastasised lymph…”
Get full text

CARDIAC TOXICITY OF TRASTUZUMAB: EXPERIENCE AT THE GHENT UNIVERSITY HOSPITAL, BELGIUM by Lamot, C., Rottey, S., De Backer, T., Van Bortel, L., Robays, H., Van Belle, S., Denys, H., Cocquyt, V.

“…Introduction Trastuzumab (TRAS) is a humanised monoclonal antibody that is targeted against the HER2 growth factor receptor. Over-expression of the receptor…”
Get full text

The Role of Oncoplastic Surgery in Breast Cancer by Hamdi, M., Sinove, Y., DePypere, H., Broucke, Van Den, Vakaef, L., Cocquyt, V., Villeirs, G., Lambein, C., Van Maele, G.

“…The authors discuss the objectives of oncoplastic surgery in breast cancer management. Indications and advantages are summarised. Some surgical techniques are…”
Get full text